JP Morgan has initiated coverage on CRISPR Therapeutics AG (CRSP) with an Overweight rating as of September 17, 2025. This marks the firm's first assessment of the company's investment potential, reflecting its research into the biotechnology sector and CRISPR's growth prospects.
CRISPR Therapeutics, headquartered in Zug, Switzerland, is a gene editing company that develops transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The firm aims to apply this technology to disrupt, delete, correct, and insert genes to treat genetically-defined diseases and engineer advanced cellular therapies. Currently, CRISPR Therapeutics employs 393 full-time staff and has a market capitalization of $4.7 billion. The company reported an earnings per share (EPS) of -5.58 in its trailing twelve months.
Upcoming earnings reports are scheduled for May 4, 2026, with an EPS estimate of -1.13 and revenue expected at $13.6 million, followed by another report on August 3, 2026, with similar EPS estimates. Recent performance has shown a notable surprise in Q3 2025, where the EPS was -1.17, exceeding expectations by 8.6%.
The move underscores the growing interest in CRISPR's innovative approach within the biotechnology industry. Analyst ratings serve as professional opinions based on extensive research, providing useful insights into potential investment opportunities. However, these assessments are subject to change as new information emerges and should be considered alongside various other factors, including company fundamentals and market dynamics.